Ebewe Pharma

Activities: Manufacturing Hi Tech Manufacturing

Ebewe specialize in technologies and applications in the fields of specialty pharmaceuticals(immunology and oncology) and contract manufacturing.

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  3. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  4. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  5. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Pharmaceutical

Brussels approves acquisition of Ebewe by Novartis

<p>The European Commission has granted competition approval to the takeover of Austria's generic pharmaceuticals company Ebewe SP by Swiss drugmaker Novartis, enabling the Euro 1.3bn deal to go ahead. Although Novartis makes generic medicines through its Sandoz division, the EC concluded that the deal &quot;would not significantly impede effective competition&quot; in Europe. </p>
Media

Novartis to add EBEWE Pharma generic injectables business to Sandoz division

<p>Novartis is to acquire the generic injectables business of Austrian company EBEWE Pharma for Euro 925m (US$1.2bn), providing its Sandoz generic pharmaceuticals division with an opportunity to grow while improving access to many generic oncology medicines.</p>
Subscribe now